Trial intelligence / Profile preview

Phase III first-line comparison of R-CVP versus R-FC lite in older or unfit patients with follicular lymphoma

2008-004759-31Phase 3Unknown

Sponsor: University of Liverpool
Start: Apr 2009
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, vincristine, prednisolone and fludarabine in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by University of Liverpool. Primary endpoints: Progression-free survival and Grade 3-4 infection. Status: unknown.

Drugs

rituximabcyclophosphamidevincristineprednisolonefludarabine

Conditions

follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)

Beyond the preview

Go deeper on 2008-004759-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-004759-31.